Furthemore, p53 mutated HCT8 cells and DLD1 cells are more resistant to CBT treatment than HCT116 cells and LoVo cells also demonstrate the need for p53 signaling so that CBT can exert its function in colorectal cancer cells. This evidence concerns the gene TP53 and colorectal cancer.